cells

Multiple Cancer Types Trials
Enrolling Now

Multiple Cancer Types
(Domvanalimab + Zimberelimab)

Overview

Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab as monotherapy and in combination with zimberelimab in participants with advanced solid malignancies.

Key Eligibility Criteria

  • Pathologically confirmed non-small cell lung cancer, squamous cell carcinoma of the head and neck, renal cell carcinoma, breast cancer, colorectal cancer, melanoma, bladder cancer, ovarian cancer, endometrial cancer, Merkel cell carcinoma, or gastroesophageal cancer that is metastatic, advanced, or recurrent with progression for which no alternative or curative therapy exists or standard therapy is not considered appropriate by the participant and treating physicianEastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • No prior malignancy active within the previous year except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer

Domvanalimab + Zimberelimab Clinical Trial Locations

clinicaltrials.gov

arrow

Multiple Cancer Types (Zimberelimab)

Overview

A phase 1b open-label study to evaluate the safety and clinical activity of zimberelimab in biomarker-selected participants with advanced solid tumors.

Key Eligibility Criteria

  • Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • No prior treatment with an anti-PD-L1, anti-PD-1, anti-CTLA-4, other immune checkpoint inhibitor or agonist, or temozolomide as monotherapy or in combination.

Clinical Trial Locations

clinicaltrials.gov

arrow

Multiple Cancer Types (Zimberelimab)

Overview

A Phase 1 Study to Evaluate the Safety and Tolerability of AB122 in Subjects with Advanced Solid Tumors.

Key Eligibility Criteria

  • Male or female subjects; age ≥ 18 years at the time of screening
  • Pathologically confirmed non-small-cell lung cancer, squamous cell carcinoma of the head and neck, renal cell carcinoma, breast cancer, colorectal cancer (CRC), prostate cancer, melanoma, bladder cancer, ovarian cancer, endometrial cancer, Merkel cell carcinoma, or gastroesophageal cancer that is metastatic, advanced or recurrent with progression for which no alternative or curative therapy exists or standard therapy is not considered appropriate by the subject and treating physician (reason must be documented in medical records)
  • ECOG performance status of 0 or 1
  • Must have at least 1 measurable lesion per RECIST. Subjects with prostate cancer who have bone-only lesions must have progression of 2 lesions or a new lesion and rising prostate-specific antigen levels. The measurable lesion must be outside of a radiation field if the subject received prior radiation
  • Up to 5 lines of prior systemic therapies for advanced/recurrent and progressing disease (an unlimited number of prior hormonal therapies is allowed)

Clinical Trial Locations

Australia ,  New South Wales

  • Kogorah , Australia ,  New South Wales ,  2217,   Active and recruiting
  • Liverpool , Australia ,  New South Wales ,  2170,   No longer recruiting

AU & NZ Clinical Trials
Registry (ANZCTR)

arrow

Healthcare Professionals: to learn more about Arcus trials, email [email protected]

Patients and Caregivers: Talk to your doctor if you are interested in learning more about Arcus clinical trials.

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

Next: Publications >>

Arcus Biosciences is a registered trademark of Arcus Biosciences, Inc.
© 2020 Arcus Biosciences, Inc.  All rights reserved.
3928 Point Eden Way, Hayward, CA 94545